Evidence map›Paper›PMID 42142041›Full record

ArticleHematological oncology2026

Extended Versus Standard Hypomethylating Agent Dosing in Combination With Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Georgio Medawar, Jean-Sebastien Anoma, Elizabeth Hill, Serena Tharakan, Dahniel L Sastow, Vincent Lok, Su Bin Hahn, Sarah Chen, Thomas Kehoe, Chidambaram Ramasamy and 6 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Georgio MedawarDepartment of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0001-9327-194X
Jean-Sebastien AnomaDepartment of Public Health, Biostatistics Shared Resources, Medical University of South Carolina, Charleston, South Carolina, USA.
Elizabeth HillDepartment of Public Health, Biostatistics Shared Resources, Medical University of South Carolina, Charleston, South Carolina, USA.ORCID https://orcid.org/0000-0003-0896-4106
Serena TharakanDepartment of Hematology-Oncology, Weill Cornell Medicine, New York, New York, USA.
Dahniel L SastowDepartment of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Vincent LokDepartment of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.ORCID https://orcid.org/0000-0001-8704-3174
Su Bin HahnDepartment of Family & Community Medicine, University of California San Francisco, San Francisco, California, USA.
Sarah ChenDepartment of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Thomas KehoeDepartment of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Chidambaram RamasamyDepartment of Hematology-Oncology, University of Connecticut, Farmington, Connecticut, USA.
Julian Guetta-WeissDepartment of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.
Kapil MeleveeduDepartment of Hematology-Oncology, University of Connecticut, Farmington, Connecticut, USA.
Chenyu LinDepartment of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-4542-4232
David M SwobodaDepartment of Hematology-Oncology, Tampa General Hospital Cancer Institute, Tampa, Florida, USA.
Douglas TremblayDepartment of Hematology-Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Alexander ColtoffDepartment of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal duration of hypomethylating agent (HMA) therapy combined with venetoclax (Ven) in newly diagnosed acute myeloid leukemia (ND-AML) remains uncertain. Standard of care (SOC) uses 5-day decitabine (Dec-5) or 7-day azacitidine (Aza-7), while extended HMA regimens (e.g., 10-day decitabine [Dec-10] during cycle 1) have also been explored, although direct comparative data between these approaches are limited. We conducted a large retrospective analysis of 335 patients with ND-AML treated at five US centers with Dec-10/Ven (n = 102) or SOC HMA/Ven (n = 233). Baseline characteristics were largely balanced, though the Dec-10 group had more treated secondary AML, and the SOC group had more intermediate risk by ELN-2024. Dec-10/Ven exhibited significantly higher composite complete remission rates (CRc) (82% vs. 70%, p = 0.029), but similar measurable residual disease (MRD) negativity rates (27% vs. 25%, p = 0.6) at best response. Median overall survival (OS) was significantly longer for Dec-10/Ven, 22.2 versus 9.1 months for SOC (p < 0.001). Transplantation was more frequent following Dec-10/Ven (25% vs. 6%, p < 0.001). The 30-day and 60-day mortality rates were similar (7% vs. 11%, p = 0.4; 13% vs. 23%, p = 0.1). On multivariable analysis, the Dec-10 regimen, de novo AML, non-complex karyotype, and IDH2 mutation were associated with a significantly lower risk of death. Our findings suggest that Dec-10/Ven may lead to improved transplant rates and survival, providing valuable real-world support for this intensified approach in appropriate patients. Prospective randomized evaluation is warranted.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsDNA MethylationLeukemia, Myeloid, AcuteSulfonamidesAdultAgedAged, 80 and overAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineFemaleHumansMaleMiddle AgedRetrospective StudiesAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineSulfonamidesvenetoclaxacute myeloid leukemiaazacitidinedecitabinedurationoutcomes

Identifiers

PMID42142041
PMCPMC13179734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.